Loading
Maravai Lifesciences Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Dec 2025.
Maravai Lifesciences Holdings, Inc.: what insiders have been doing
Maravai Lifesciences Holdings, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 24 filings came from 10 insiders.
The flow runs one way only: 2 insiders bought (3 purchases totalling €1.2M) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive and 1 chief executive. Brust Bernd filed the largest purchase, €606k, on 17 November 2025.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 24 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 5 purchases and 1 sale. The 10-K for the year ended 31 December 2025 shows 185.7 m USD of revenue and -130.8 m USD of net income.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 9 December 2025, which is 313 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
165
Thresholds
n/a
Buy Volume
€2M
5 ops. · all time
Sell Volume
€120,945
1 ops. · all time
Who traded when
BuySaleBernd Brust2 buys
Gregory T. Lucier1 buy
Hull Carl1 buy
John A. DeFord1 buy
Oreshack Kurt1 sale
Since the insiders bought
- -6.2%Entry US$3.73 · Close at T+90 US$3.50
- -19.1%Entry US$3.62 · Close at T+90 US$2.93
- -24.4%Entry US$4.42 · Close at T+365 US$3.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Maravai Lifesciences Holdings, Inc. Buy (bullish), based on 6 analysts. Average price target: US$7.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,627 of 24,148 companies
17.8
score / 100
Value24
Quality11
FCF yld-2.7%
Earn yld-5.0%
EV/EBITDA·
ROE-33%
Gross mgn18%
Net mgn-70%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.53
Analyst consensus
6 analystsBuy
US$7.00Target US$7.83(+20%)US$9.00
Income statement
RevenueUS$185.7M
Gross profitUS$34M18% margin
EBITDA-US$147.5M-79% margin
Net income-US$130.8M-37.1% margin
Valuation
PER (forward)-64.9x
P/Book4.8x
Beta0.54
Balance sheet & cash
Market capUS$2.4B
Total debtUS$364.7M
Free Cash Flow-US$70.7M
Debt / Equity61%
Profitability & ownership
ROE-33.0%
ROA-5.7%
% insiders7.2%
% institutions99.1%
Last declaration on 9 October 2026
Declarations165 total
29,250 shares@ US$7.430.0082% mcap11.2% of flowClass A Common StockSEC:0001380632-26-000010:0
5,465 shares@ US$7.650.0015% mcap35.3% of flowClass A Common StockSEC:0001600301-26-000008:0
29,250 shares@ US$7.320.0074% mcap11.9% of flowClass A Common StockSEC:0001380632-26-000008:0
5,465 shares@ US$7.680.0015% mcap53.5% of flowClass A Common StockSEC:0001600301-26-000006:0
29,250 shares@ US$6.230.0064% mcap10.2% of flowClass A Common StockSEC:0001380632-26-000006:0
5,465 shares@ US$6.590.0013% mcap46.5% of flowClass A Common StockSEC:0001600301-26-000004:0
29,250 shares@ US$5.920.0061% mcap9.9% of flowClass A Common StockSEC:0001380632-26-000004:0
65,584 sharesClass A Common StockSEC:0001600301-26-000002:0
25,000 shares@ US$5.100.0056% mcap13.4% of flowClass ASEC144:0001959173-26-004507
351,001 sharesClass A Common StockSEC:0001380632-26-000002:0
25,000 shares@ US$5.060.0056% mcap13.3% of flowClass ASEC144:0001959173-26-004463
46,293 shares0Class A Common StockSEC:0001829753-26-000001:0
46,293 shares0Class A Common StockSEC:0001403373-26-000005:0
46,293 shares0Class A Common StockSEC:0001210525-26-000001:0
46,293 shares0Class A Common StockSEC:0001833453-26-000004:0
5,006 shares@ US$1.790.0004% mcap1.6% of flowClass A Common StockSEC:0001684273-26-000005:0
39,976 shares@ US$3.0813.1% of flowClass A Common StockSEC:0001832579-26-000003:0
28,661 shares@ US$3.0816.2% of flowClass A Common StockSEC:0001684273-26-000003:0
31,902 shares@ US$3.6912.3% of flowClass A Common StockSEC:0001832579-26-000001:0
28,934 shares@ US$3.6919.2% of flowClass A Common StockSEC:0001684273-26-000001:0
51,472 shares@ US$3.700.0091% mcap30.5% of flowClass A Common StockSEC:0001251299-25-000004:0
Canonical exit: 5 Mar 2026 (T+90)
4,300 shares@ US$1.791.4% of flowClass A Common StockSEC:0001684273-25-000004:0
216,212 shares@ US$3.2539.4% of flowClass A Common StockSEC:0001380632-25-000006:0
Canonical exit: 11 Feb 2026 (T+90)
157,201 shares@ US$3.2428.6% of flowClass A Common StockSEC:0001380632-25-000004:0
Canonical exit: 9 Feb 2026 (T+90)
5,154 shares@ US$2.593.8% of flowClass A Common StockSEC:0001823239-25-000097:0
25 of 165 declarations
About Maravai Lifesciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (MRVI) is a US life sciences company listed on the NASDAQ, meaning it trades on the American market in the United States. For French-speaking investors evaluating the name, Maravai is best understood as an enabling-tools and reagents platform for biopharma rather than a drug developer. The company provides critical products and services that support the development and manufacture of vaccines, therapeutics and diagnostics, with an operating model built around two core segments: TriLink, historically associated with nucleic acid production, and Cygnus, focused on biologics safety testing. That structure gives Maravai exposure to multiple stages of the life-science value chain, from discovery and research through manufacturing and quality control.
The company was founded in 2014 and is headquartered in San Diego, California, a major US biotechnology hub. Over time, Maravai has built a portfolio of technologies and brands around nucleic acid synthesis, mRNA-related materials, and biologics testing solutions. Its customer base includes major biopharmaceutical companies, emerging biotech firms, academic research institutions and diagnostics companies. This diversification is helpful, although demand can still be influenced by biotech funding cycles, vaccine-related volume swings and customer concentration trends in certain product lines.
Read moreShow less
From a competitive standpoint, Maravai occupies a specialized and strategically important niche. In the life sciences ecosystem, companies like MRVI compete on reliability, technical know-how, regulatory compliance, product quality and supply assurance rather than on price alone. Those capabilities matter because customers are often operating in highly regulated environments and need trusted suppliers for mission-critical workflows. Maravai also emphasizes its global commercial reach, serving customers across North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin and Central America.
Recent corporate developments have remained important for the investment case. Maravai reported first-quarter 2026 results and highlighted improvement in base revenue excluding high-volume CleanCap revenue tied to commercialized COVID-19 vaccines. The company has also continued to reference domestic manufacturing capacity for mRNA-related products and has seen governance and leadership changes over the past year, which investors will likely view as part of a broader cost and portfolio optimization effort. Overall, MRVI remains a health and pharma infrastructure story: strategically relevant technologies, global customer exposure, and earnings sensitivity to post-pandemic normalization and broader biotech market conditions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
